# Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

> **NCT01591655** · PHASE3 · COMPLETED · sponsor: **Bausch & Lomb Incorporated** · enrollment: 360 (actual)

## Conditions studied

- Cataract
- Inflammation
- Surgery

## Interventions

- **DRUG:** Mapracorat
- **DRUG:** Vehicle

## Key facts

- **NCT ID:** NCT01591655
- **Lead sponsor:** Bausch & Lomb Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2013-09
- **Final completion:** 2013-10
- **Target enrollment:** 360 (ACTUAL)
- **Last updated:** 2020-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01591655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01591655, "Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01591655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*